Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3180741rdf:typepubmed:Citationlld:pubmed
pubmed-article:3180741lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:3180741lifeskim:mentionsumls-concept:C0023516lld:lifeskim
pubmed-article:3180741lifeskim:mentionsumls-concept:C0009521lld:lifeskim
pubmed-article:3180741lifeskim:mentionsumls-concept:C0033603lld:lifeskim
pubmed-article:3180741lifeskim:mentionsumls-concept:C0056196lld:lifeskim
pubmed-article:3180741lifeskim:mentionsumls-concept:C0680242lld:lifeskim
pubmed-article:3180741pubmed:issue3lld:pubmed
pubmed-article:3180741pubmed:dateCreated1988-12-14lld:pubmed
pubmed-article:3180741pubmed:abstractTextIt is shown that protamine selectively and dose-dependently inhibits complement C5a-induced leukocyte responses such as histamine release from basophils, chemiluminescence and beta-glucuronidase release from neutrophils. Protamine produces parallel rightward displacements of the C5a dose-response curves. The inhibitory capacity of the polypeptide is reversible and disappears following repeated washing of exposed cells. In neutrophils poly-L-Arg similarly and specifically antagonizes C5a-induced chemiluminescence and enzyme release. This polymer alone, however, degranulates basophils and neutrophils, leading to histamine and enzyme release, respectively. It is concluded that on human neutrophils the arginine-rich polycations protamine and poly-L-Arg exhibit a competitive C5a receptor antagonism. In addition, protamine inhibits the C5a receptors on basophils. It is hypothesized that molecular conformations of the arginine-rich polycations might bind reversibly to, and block negatively charged groups at the C5a-receptor sites.lld:pubmed
pubmed-article:3180741pubmed:languageenglld:pubmed
pubmed-article:3180741pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:citationSubsetIMlld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3180741pubmed:statusMEDLINElld:pubmed
pubmed-article:3180741pubmed:issn0253-5076lld:pubmed
pubmed-article:3180741pubmed:authorpubmed-author:OlsenU BUBlld:pubmed
pubmed-article:3180741pubmed:authorpubmed-author:KralV AVAlld:pubmed
pubmed-article:3180741pubmed:authorpubmed-author:SelmerJJlld:pubmed
pubmed-article:3180741pubmed:issnTypePrintlld:pubmed
pubmed-article:3180741pubmed:volume5lld:pubmed
pubmed-article:3180741pubmed:ownerNLMlld:pubmed
pubmed-article:3180741pubmed:authorsCompleteYlld:pubmed
pubmed-article:3180741pubmed:pagination153-62lld:pubmed
pubmed-article:3180741pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:meshHeadingpubmed-meshheading:3180741-...lld:pubmed
pubmed-article:3180741pubmed:year1988lld:pubmed
pubmed-article:3180741pubmed:articleTitleComplement C5a receptor antagonism by protamine and poly-L-Arg on human leukocytes.lld:pubmed
pubmed-article:3180741pubmed:affiliationDepartment of Pharmacology, NOVO Industri A/S, Bagsvaerd, Denmark.lld:pubmed
pubmed-article:3180741pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:3180741pubmed:publicationTypeIn Vitrolld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3180741lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3180741lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3180741lld:pubmed